Nara F, Tanaka M, Masuda-Inoue S, Yamasato Y, Doi-Yoshioka H, Suzuki-Konagai K, Kumakura S, Ogita T
Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
J Antibiot (Tokyo). 1999 Jun;52(6):531-5. doi: 10.7164/antibiotics.52.531.
Scyphostatin is a specific inhibitor for mammalian neutral magnesium-dependent sphingomyelinase with a fifty percent inhibition concentration (IC50) value of 1.0 microM. When used to inhibit lysosomal acid sphingomyelinase, an approximately 50-fold greater concentration is required. In human peripheral monocytes, the compound inhibits bacterial lipopolysaccharide (LPS)-induced prostaglandin E2 production and LPS-induced interleukin-1beta production with IC50 values of 0.8 microM and 0.1 microM, respectively. In rat, p.o. administration of the compound has also been shown to inhibit carrageenin-induced paw edema. Thus, it is hoped that utility of scyphostatin as a pharmacological tool will contribute to our understanding of the role of ceramide in the cellular inflammation process.
水母鞘氨醇是一种针对哺乳动物中性镁依赖性鞘磷脂酶的特异性抑制剂,其半数抑制浓度(IC50)值为1.0微摩尔。当用于抑制溶酶体酸性鞘磷脂酶时,所需浓度大约高50倍。在人外周血单核细胞中,该化合物抑制细菌脂多糖(LPS)诱导的前列腺素E2生成和LPS诱导的白细胞介素-1β生成,IC50值分别为0.8微摩尔和0.1微摩尔。在大鼠中,口服该化合物也已显示可抑制角叉菜胶诱导的爪肿胀。因此,希望水母鞘氨醇作为一种药理学工具的效用将有助于我们了解神经酰胺在细胞炎症过程中的作用。